Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Tekturna - labeled renal guidance
Product / population
Aliskiren hemifumarate (Tekturna), oral tablet
Renal method
Renal impairment categories as defined by the cited product label
Renal method: Renal impairment categories as defined by the cited product label Source date: DailyMed SPL version 16, posted Mar 12, 2024 Retrieved: 2026-11-07
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Renal guidance: 5.2 Renal Impairment/Hyperkalemia/Hypotension when Tekturna is Given in Combination with ARBs or ACEIs / 5.5 Impaired Renal Function / 8.6 Renal Impairment
Aliskiren is contraindicated with an ACE inhibitor or ARB in diabetes because the combination increases the risk of kidney injury, hypotension and hyperkalemia. This is an interaction restriction. Review combined renin-angiotensin blockade, potassium, and renal function.
RDM74-tekturna-official-1 · Source locator: Renal guidance: 5.2 Renal Impairment/Hyperkalemia/Hypotension when Tekturna is Given in Combination with ARBs or ACEIs / 5.5 Impaired Renal Function / 8.6 Renal Impairment
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
